Manus Neurodynamica - Model NMP - NeuroMotor Pen
Highly accurate sensor technologies built into the NeuroMotor Pen. Analytical engine with Decision Support System. User interface to non-invasively record and analyse parameters of minute limb and hand motion and quantify fine motor skill, represented by ‘motion features’. Motion features are translated into biomarkers to provide objective information about movement abnormalities which support diagnosis and monitoring of Parkinson's disease and other impairments. Full audit trail of results. Full monitoring of changes over time. Patented and CE marked as a medical device. Manufacturing setup with QMS according to all relevant standards in place.
Product Benefits
- For specialists
- Increase certainty of differential diagnosis, especially Parkinson's versus Essential Tremor
- Monitor disease severity for improved treatment
- Reduced cost compared to DaTscan assessment
- Improve accuracy where there is insufficient access to skilful consultants
- Improve departmental efficiency
- Reduce delays in diagnosis and implementation of treatment
- Patients experience a simple, non-threatening test
- Patient monitoring by non-specialist nurses to optimise treatment with cost reduction
For GP’s
- Triage use to increase referral accuracy and save on costs for 50% unnecessary referrals (UK)
- In non-neurological care settings to use as a screening tool for pre-symptomatic screening of apparently healthy individuals in groups at risk
Pharms, R&D
- Ensure subjects recruited for trials are correctly identified as PD or non-PD
- Support the evaluation of pharmaceutical interventions during trials
- Measure the change in severity of the movement disorder throughout the trial
Data Security
Manus Neurodynamica has implemented best-in-class encryption & cloud security technology providing:
- Dedicated Microsoft Windows IoT with integrated Manus NMP app installation
- A secure and locked down tablet device dedicated to NMP
- Encryption and anonymisation of data on the tablet
- Secure Cloud infrastructure, storage and data transport
- Complex workflow implementation for software updates, licensing and remote device management
Manus Neurodynamica is a member of the Microsoft™ Partner program.
How the NeuroMotor Pen
The NeuroMotor Pen™ offers an accurate and objective assessment for differential diagnosis and clinical management of patients with neuromotor impairments, as well as supporting drug management which can change a patient's neuromotor functions.
Patients complete a set of standardized NeuroMotor™ Pen handwriting and drawing tasks with the NeuroMotor™ Pen App on a high-end tablet PC. The tasks were developed to derive as much information about the subject's neuromotor processing with relatively few tasks. The Pen has a wireless connection with the tablet from where the data is sent to the cloud application, where the NeuroMotor™ Pen algorithms analyse the minute limb and hand motion to provide the results in the App. SmartPoints™ cybersecurity to medical standards is applied on the tablet, as well as for the data in transit and on the cloud.
The results of the NeuroMotor Pen™ motor skill tests are presented as biomarkers with an easy to interpret numerical format on the graphical user interface.
The NeuroMotor™ Pen with analytical software that calculates the biomarkers can non-invasively differentiate between Parkinson's and other disease or signs normal ageing that may mimic the symptoms of Parkinson's disease. In addition to scoring biomarkers, a second level of outcome presentation allows to categorise the results in, for example, likelihood of Parkinson's vs Essential Tremor or other disease classification.
Manus Neurodynamica provides a robust and secure data-processing and analysis architecture including a cloud-based facility to allow clinicians to store the test data safely and anonymously.
The Application
Early diagnosis and timely access to specialist care is essential for patients with Parkinson's disease. Typically 70% of the economic burden of Parkinson's disease is related to long-term disability.
If early deterioration can be avoided, long-term outcomes will be better and pre-symptomatic screening will become increasingly important when neuroprotective or regenerative therapies become widely available within the next 2-5 years.
Current diagnostic methods for Parkinson's disease are based on the clinician's subjective interpretation. Even for experienced clinicians, differentiating between a Parkinson's disease tremor and other tremors, such as an essential tremor, can be difficult and an unequivocal diagnosis of Parkinson's disease cannot always be made.
In such cases, neuroimaging techniques (DaTSCAN), which are expensive, require skilled operators and can be unpleasant for patients. Other methods for analysis of neurophysiological signals are impractical and no reliable comparison can be made from interpretations of observations and histories that were taken by different physicians or at different points in time, and the assessment is not objective.
The NeuroMotor Pen can increase the certainty of diagnosis by recognising differential diagnostic and disease progression biomarkers of Parkinson's disease. The results will non-invasively differentiate between Parkinson's disease and other neuromotor impairments such as essential tremor or signs of normal ageing which may mimic the symptoms of Parkinson's disease.
Regular use of the NeuroMotor Pen enables the clinician to monitor the patient's response to medication and disease progression.
Customer reviews
No reviews were found for Manus Neurodynamica - Model NMP - NeuroMotor Pen. Be the first to review!